Pharmacy Technician Pulse

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag wet-amd

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

pharmaphorum

NOVEMBER 19, 2020

Lucentis (ranibizumab) was first FDA approved in 2006 for wet age-related macular degeneration (wet AMD) and has picked up approvals in related eye conditions ever since, although its patent expired in June.

FDA

FDA Labelling

PharmaShots Weekly Snapshots (February 13 - 17, 2023)

PharmaShots

FEBRUARY 17, 2023

Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)

FDA

FDA Vaccines

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

PharmaShots Weekly Snapshots (February 13 - 17, 2023)

Stay Connected